Sylvie Bouchard graduated in pharmacy at Laval University in Quebec. She also holds a diploma and a master’s degree in hospital pharmacy as well as an MBA in business management, obtained at the same university. In 2017, the Ordre des pharmaciens du Québec awarded her the Louis-Hébert Prize, the highest distinction for the recognition of excellence in her professional achievements, throughout her career.
Ms. Bouchard worked as a pharmacist in the health care facility and as a hospital pharmacy manager, first at the hospital affiliated university center of Quebec (CHAUQ) and the Hôtel-Dieu de Québec Center hospitalier universitaire de Québec ( CHUQ). She has worked in several clinical areas, with a marked interest in intensive care practice. In addition, it implemented robotization and drug distribution technologies at CHAUQ in 2001.
She joined the Medicines Council in April 2010, which became the National Institute of Excellence in Health and Social Services (INESSS) in 2011, and assumed several managerial roles. Ms. Bouchard held the position of Director drug as of April 2016. She is now director of drug evaluation and technology for purposes of reimbursement.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
Adapt Your Strategy to an Uncertain Marketplace and Succeed in Securing Public Payer PLA’s
Getting products listed for reimbursement with public payers can be challenging in a transitional, uncertain market. Get the insight you need to meet the expectations of INESSS and the pCPA to navigate your new product through their submission processes. Walk away with an action plan for your public PLA submission strategy by:
- Understanding the types of products provinces need
- Reviewing your value proposition to be sure it meets INESSS and pCPA expectations
- Gaining valuable insight on any changes on the horizon for public PLA submission requirements
Position your company to succeed in an uncertain environment with a solid public PLA strategy
Day 3: Oct 8, 2020